RxSight, Inc. (NASDAQ:RXST) Insider Sells $142,228.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total value of $142,228.00. Following the sale, the insider now owns 42,246 shares in the company, valued at approximately $1,938,246.48. The trade was a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total transaction of $139,500.00.
• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The shares were sold at an average price of $46.00, for a total transaction of $224,250.00.
• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total value of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total value of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total value of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.79, for a total value of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.

RxSight Stock Performance

NASDAQ RXST opened at $46.40 on Thursday. RxSight, Inc. has a one year low of $28.88 and a one year high of $66.54. The company’s 50 day moving average price is $49.00 and its 200 day moving average price is $52.48. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -55.78 and a beta of 1.19.

Hedge Funds Weigh In On RxSight

Several hedge funds and other institutional investors have recently made changes to their positions in RXST. Vanguard Group Inc. increased its holdings in RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after purchasing an additional 40,500 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of RxSight by 1.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock valued at $3,143,000 after buying an additional 994 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of RxSight by 6.8% during the 1st quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock valued at $1,395,000 after buying an additional 1,733 shares during the period. RA Capital Management L.P. lifted its position in RxSight by 1.1% during the 1st quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after acquiring an additional 38,540 shares in the last quarter. Finally, CWM LLC boosted its holdings in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on RXST shares. Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective on the stock. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.